Plain-English translation of NCT04516681 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , an immunotherapy medication, works better when combined with intravenous vitamin C infusions and standard chemotherapy for advanced colorectal cancer. The study focuses on patients whose cancer cells have high levels of a specific protein called GLUT3, which lab research suggests may make vitamin C treatment more effective. Researchers believe this combination approach may help the body's immune system fight the cancer more effectively than chemotherapy alone.
Early laboratory studies show that vitamin C can kill colorectal cancer cells, especially in cancers with high GLUT3 protein levels. This trial exists to test whether combining this medication with the body's own immune system (through an immunotherapy drug) alongside standard chemotherapy can extend survival and improve outcomes better than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to one of two groups: one group will receive intravenous vitamin C infusions (given on days 1–3 every 2 weeks) plus standard chemotherapy and the immunotherapy medication , while the other group will receive standard chemotherapy alone. You will have regular hospital or clinic visits for infusions, blood tests, and imaging scans to monitor how well the treatment is working and check for side effects. The trial is enrolling 400 people and will continue until researchers have enough information to determine whether the combination treatment works better than chemotherapy alone.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China